Clinical trial
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
NCT02308111 is registered in ClinicalTrials.gov with Intercept Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
- Lead sponsor
- Intercept Pharmaceuticals
- Phase
- Phase 4
- Overall status
- Terminated
- Start date
- December 26, 2014
- Completion date
- December 23, 2021
- Enrollment
- 334 (actual)
- Sites
- 181
Conditions
As the registry lists them; a condition with its own page is linked.